首页> Archives of toxicology> Alignment between Duplex Sequencing and transgenic rodent mutation assay data in the assessment of in vivo NDMA-induced mutagenesis.

Alignment between Duplex Sequencing and transgenic rodent mutation assay data in the assessment of in vivo NDMA-induced mutagenesis.

导出 OA

翻译打印收藏纠错

第一作者： Anne L,Ashford

第一单位： Safety Innovation, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. anne.ashford@astrazeneca.com.

作者： Anne L,Ashford ^[1] ; Daniela,Nachmanson ^[2] ; John W,Wills ^[3] ; Jacob E,Higgins ^[2] ; Thomas H,Smith ^[2] ; Kevin C,Vavra ^[2] ; Farah A,Dahalan ^[4] ; Jonathan,Howe ^[5] ; Joanne M,Elloway ^[4] ; Jesse J,Salk ^[6] ; Ann,Doherty ^[4] ; Anthony M,Lynch ^[7]

作者单位： Safety Innovation, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. anne.ashford@astrazeneca.com. ^[1] TwinStrand Biosciences, Inc., Seattle, WA, USA. ^[2] Systems Toxicology and Data, GSK Research & Development, Stevenage, SG1 2NY, UK. ^[3] Safety Innovation, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. ^[4] Genetic & Investigative Toxicology, GSK Research & Development, Stevenage, SG1 2NY, UK. ^[5] TwinStrand Biosciences, Inc., Seattle, WA, USA.;Department of Medicine, Division of Hematology and Oncology, University of Washington, Washington, USA. ^[6] Genetic & Investigative Toxicology, GSK Research & Development, Stevenage, SG1 2NY, UK.;School of Medicine, Swansea University, Singleton Park, Swansea, SA2 8PP, UK. ^[7]

关键词 Benchmark dose Error-corrected sequencing Genetic toxicology Nitrosamine Non-clinical safety